Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2016 - 2025)

Enanta Pharmaceuticals' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 38.36% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.9 million, up 90.75%, while the annual FY2025 figure was $4.6 million, 96.32% up from the prior year.
  • Depreciation & Amortization (CF) reached $1.2 million in Q4 2025 per ENTA's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q3 2025 to a low of $479000.0 in Q3 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $797950.0, with a median of $748000.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 34.49% in 2022, then surged 168.06% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $780000.0 in 2021, then tumbled by 34.49% to $511000.0 in 2022, then rose by 25.64% to $642000.0 in 2023, then skyrocketed by 38.47% to $889000.0 in 2024, then surged by 38.36% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Depreciation & Amortization (CF) are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025).